LAS VEGAS, NV, OCT. 18, 2006—The patent owner of Cran-Max® cranberry supplement, Bio-Nutra Technologies, LLC, Venice, FL, today announced it has filed a patent infringement and unfair competition suit against Decas Cranberry Products, Inc., and Decas Botanical Synergies, LLC, Wareham, MA., marketer of PACran.
“We believe, based on the manufacturing process, content, and dosage of PACran that it infringes on Bio-Nutra Technologies’ patent,” said Doug Mann, managing director. “In addition, Decas has claimed in its marketing materials, that PACran is the only cranberry supplement clinically studied for urinary tract infections (UTIs). Cran-Max is supported by several clinical studies showing efficacy for UTIs, as early as 1998,” said Mann. “In fact, in some of its product literature, Decas references a cranberry study published in the Canadian Journal of Urology, June 9, 2002, which demonstrated clinical effectiveness. This study was actually conducted using Cran-Max as the cranberry supplement.”
# # #